ArticleTranslational andrology and urology2026
Comprehensive multi-omics analysis identifies molecular subtypes and AMH-dependent mechanisms driving DTX resistance in prostate cancer.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer (PCa) remains one of the most prevalent malignancies and a leading cause of cancer-related mortality among men worldwide. Despite advancements in treatment, therapeutic resistance, particularly to docetaxel (DTX), significantly limits clinical efficacy and worsens patient outcomes. Methods: Transcriptomic profiles and matched clinical data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) were integrated for analysis. Differentially expressed genes linked to DTX resistance were screened to classify PCa patients into molecular subtypes. Bulk transcriptome-based drug sensitivity estimation and immune pathway enrichment analysis were performed to compare subtype-specific features. Single-cell transcriptomic data were further applied to resolve epithelial cell heterogeneity and interrogate the biological function of Results: Two discrete molecular subtypes (C1 and C2) were established based on DTX resistance-related gene signatures. The C1 subtype displayed an aggressive phenotype with shorter progression-free survival (PFS), unique mutational landscapes, and activated immunosuppressive pathways. Subtypes also showed divergent sensitivity to multiple anticancer agents. Single-cell results demonstrated that Conclusions: Collectively, these findings highlight the cellular and molecular heterogeneity associated with DTX resistance in PCa and provide new insights into the molecular characteristics of DTX resistance. These results may facilitate the identification of candidate biomarkers and potential therapeutic targets, although further experimental and clinical validation is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.